Skip to main content
Erschienen in: Clinical and Translational Oncology 4/2020

20.08.2019 | Author Correction

Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy

verfasst von: A. Passaro, P. Mancuso, S. Gandini, G. Spitaleri, V. Labanca, E. Guerini-Rocco, M. Barberis, C. Catania, E. Del Signore, F. de Marinis, F. Bertolini

Erschienen in: Clinical and Translational Oncology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Excerpt

Acknowledgements section was missing in the original published version. The Acknowledgement section read as follows: …
Metadaten
Titel
Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy
verfasst von
A. Passaro
P. Mancuso
S. Gandini
G. Spitaleri
V. Labanca
E. Guerini-Rocco
M. Barberis
C. Catania
E. Del Signore
F. de Marinis
F. Bertolini
Publikationsdatum
20.08.2019
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 4/2020
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02198-5

Weitere Artikel der Ausgabe 4/2020

Clinical and Translational Oncology 4/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.